Cargando…
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are required in order to overcome innate and acquired resistance to these drugs and thus expand the array of c...
Autores principales: | Yalon, Michal, Tuval-Kochen, Liron, Castel, David, Moshe, Itai, Mazal, Inbal, Cohen, Osher, Avivi, Camila, Rosenblatt, Kineret, Aviel-Ronen, Sarit, Schiby, Ginette, Yahalom, Joachim, Amariglio, Ninette, Pfeffer, Raphael, Lawrence, Yaacov, Toren, Amos, Rechavi, Gideon, Paglin, Shoshana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873128/ https://www.ncbi.nlm.nih.gov/pubmed/27196668 http://dx.doi.org/10.1371/journal.pone.0155711 |
Ejemplares similares
-
Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
por: Yalon, Michal, et al.
Publicado: (2016) -
Eukaryotic Initiation Factor 2α - a Downstream Effector of Mammalian Target of Rapamycin - Modulates DNA Repair and Cancer Response to Treatment
por: Tuval-Kochen, Liron, et al.
Publicado: (2013) -
MutT homolog 1 counteracts the effect of anti-neoplastic treatments in adult and pediatric glioblastoma cells
por: Versano, Ziv, et al.
Publicado: (2018) -
Pediatric glioblastoma cells are sensitive to drugs that inhibit eIF2α dephosphorylation and its phosphomimetic S51D variant
por: Eytan, Karin, et al.
Publicado: (2022) -
Related to testes-specific, vespid and pathogenesis protein-1 is regulated by methylation in glioblastoma
por: JACOBY, ELAD, et al.
Publicado: (2014)